This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Vertex Pharmaceuticals Inc (VRTX)

NASDAQ: Health Care

Company Income Statement
Dec 2013 Dec 2012 Dec 2011 Dec 2010
Sales 1.21B 1.53B 1.41B 143.37M
Cost of Sales 81.91M 241.69M 27.06M 12.73M
Gross Operating Profit 1.13B 1.29B 1.38B 130.64M
Selling, General, and Administrative Expenses 362.34M 436.80M 400.72M 187.80M
Research & Development 918.78M 806.18M 707.71M 637.42M
Operating Income before D & A (EBITDA) -151.06M 42.37M 275.14M -694.58M
Depreciation & Amortization 48.36M 38.19M 53.45M 44.05M
Interest Income 0.00 1.94M 1.88M 1.96M
Other Income - Net -49.94M 0.00 -16.80M -41.23M
Special Income / Charges -663.50M 0.00 -105.80M 0.00
Total Income Before Interest Expenses (EBIT) -953.39M 4.27M 98.90M -779.40M
Interest Expense 22.73M 16.65M 38.45M 19.28M
Pre-Tax Income -976.12M -12.38M 60.44M -798.67M
Income Taxes -288.57M 38.75M 19.27M 0.00
Minority Interest -242.52M 55.90M 11.60M 0.00
Net Income From Continuing Operations -687.55M -51.14M 41.18M -754.63M
Net Income From Discontinued Operations 0.00 0.00 0.00 0.00
Net Income From Total Operations -687.55M -51.14M 41.18M -754.63M
Extraordinary Income/Losses 0.00 0.00 0.00 0.00
Income From Cum. Effect of Acct. Change 0.00 0.00 0.00 0.00
Income From Tax Loss Carryforward 0.00 0.00 0.00 0.00
Other Gains / Losses 0.00 0.00 0.00 0.00
Total Net Income -445.03M -107.03M 29.57M -754.63M
Normalized Income
(Net Income From Continuing Operations,
Ex. Special Income / Charge)
16.47M -49.29M 149.05M -753.12M
Preferred Dividends
Net Income Available To Common -687.55M -51.14M 41.18M -754.63M
Basic EPS from Continuing Ops. -1.98 -0.50 0.14 -3.77
Basic EPS from Discontinued Ops. 0.00 0.00 0.00 0.00
Basic EPS from Total Operations -1.98 -0.50 0.14 -3.77
Basic EPS from Extraordinary Inc. 0.00 0.00 0.00 0.00
Basic EPS from Cum Effect of Accounting Change 0.00 0.00 0.00 0.00
Basic EPS from Tax Loss Carryf'd. 0.00 0.00 0.00 0.00
Basic EPS from Other Gains (Losses) 0.00 0.00 0.00 0.00
Basic EPS, Total -1.98 -0.50 0.14 -3.77
Basic Normalized Net Income/Share 0.05 -0.49 0.52 -3.76
EPS fr Continuing Ops. -1.98 -0.50 0.14 -3.77
EPS fr Discontinued Ops 0.00 0.00 0.00 0.00
EPS fr Total Ops. -1.98 -0.50 0.14 -3.77
EPS fr Extraord. Inc. 0.00 0.00 0.00 0.00
EPS fr Cum Effect of Accounting Change 0.00 0.00 0.00 0.00
EPS fr Tax Loss Carfd. 0.00 0.00 0.00 0.00
EPS fr Other Gains (L) 0.00 0.00 0.00 0.00
EPS, Total -1.98 -0.50 0.14 -3.77
Diluted Normalized Net Inc/Shr
(Net Income From Continuing Operations,
Ex. Special Income / Charge)
0.05 -0.49 0.51 -3.76
Dividends Paid per Share 0.00 0.00 0.00 0.00
VRTX News

VRTX Vertex Pharmaceuticals Inc

Analysts Ratings for VRTX

Rating Current 1-Mo Ago 2-Mo Ago 3-Mo Ago
Strong Buy 9 10 10 11
Moderate Buy 0 0 0 0
Hold 5 5 5 5
Moderate Sell 0 0 0 0
Strong Sell 0 0 0 0
GET VRTX ANALYST REPORT

Brokerage Partners

VRTX Chatter

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
Real Money Pro

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Trifecta Stocks

Trifecta Stocks analyzes over 4,000 equities weekly to find the elite 1% of stocks that pass rigorous quantitative, fundamental and technical tests.

Product Features:
  • Model portfolio
  • Trade alerts
  • Recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
Stocks Under $10

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Dividend Stock Advisor

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Breakout Stocks

Bryan Ashenberg, using sophisticated stock screening and fundamental research, identifies potentially explosive small and mid-cap stocks.

Product Features:
  • Model portfolio
  • Small-cap and mid-cap focus
  • Intraday trade alerts
  • Weekly roundups
Options Profits

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
Top Rated Stocks Top Rated Funds Top Rated ETFs